


DOCKET NO.: ASZN0035-100 (100911-1P US)

In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please cancel claims 34-38 without prejudice to their presentation in another application, and amend claims 3-11, 13, 14, 21, 22, 24-26, 32, 33, and 39-53 as follows:

1. (original) A compound of formula (I):



(I)

wherein:

R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_2-4 alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional substitutions are made with 0, 1, 2 or 3 R^c;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^c;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^c;

R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C_{1-6} alkyl, or C_{1-6} alkoxy;

R², R³, R⁶ and R⁷ are independently selected from H, optionally substituted 5- or 6-

membered aromatic or heteroaromatic ring, said ring having 0, 1, 2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C₁₋₃alkylaryl, optionally substituted C₁₋₃alkylheterocycle, optionally substituted C₁₋₆alkyl, or optionally substituted C₃₋₆ cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R², R³, R⁶ and R⁷ are aromatic or heteroaromatic;

R⁴ is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C₁₋₆alkyl, C₃₋₆ cycloalkyl, or CR⁹R¹⁰R¹¹;

R⁵ is -C₁₋₆alkyl, -C₁₋₃alkylR¹² or CH(OH)R¹³;

R⁹, R¹⁰ and R¹¹ are, at each occurrence independently selected from H, F, C₁₋₄alkyl, OH, OCH₃, SH, SCH₃, CH₂SCH₃;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R¹³ is C₁₋₆alkyl or R¹²;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound of claim 1, wherein:

R¹ is selected from H, or optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from C₁₋₆cycloalkyl, C₁₋₆cycloalkoxy, or phenyl;

R², R³, R⁶ and R⁷ are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R², R³, R⁶ and R⁷ are aromatic;

R⁴ is H, or C₁₋₆alkyl;

R⁵ is -C₁₋₆alkyl, -C₁₋₃alkylR¹²;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy;

or a pharmaceutically acceptable salt thereof.

3. (currently amended) A compound of claim 1, wherein:
R¹ is selected from H, -C₁₋₆alkyl, -(CH₂)₂OCH₃, -CH₂-phenyl, -CH₂C₁₋₆cycloalkyl;
R², R³, R⁶ and R⁷ are independently selected from H, or a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH₃;
R⁴ is H, or C₁₋₆alkyl;
R⁵ is -C₁₋₆alkyl, -C₁₋₃alkylR¹² wherein R¹² is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH₃;
or a pharmaceutically acceptable salt thereof.
4. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:
R¹ is ~~-C₁₋₃alkyl~~, -C₁₋₃alkyl or -CH₂C₁₋₄cycloalkyl.
5. (currently amended) A compound of claim 1, wherein:
R¹ is ~~methy~~ methyl or -CH₂cyclopropane.
6. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:
R^e is, at each occurrence independently selected from F, Cl, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy.
7. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:
R² is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.
8. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:
R³, R⁶ and R⁷ are H.
9. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:
R⁴ is C₁₋₆alkyl.

10. (currently amended) A compound of ~~claim 1~~ claim 1, wherein:

R^5 is ~~$-C_{1-6}alkyl$, $-C_{1-6}alkyl$ or $-C_{1-3}alkyl$~~ ¹² wherein R^{12} is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 .

11. (currently amended) A compound ~~of formula (I)~~ of claim 1 selected from:

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^1 -[(3S,7S)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3S,7R)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3S,7S)-1-benzyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3S,7R)-1-benzyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-hydroxy-4-methylpentanoyl]- N^1 -[(3S,7S)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-leucinamide;

N^1 -[(3R,7S)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3S,7S)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3R,7S)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3*S*,7*S*)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3*R*,7*S*)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide

N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide (11)

N^1 -[(3*R*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(2*S*)-2-hydroxy-4-methylpentanoyl]-L-leucinamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*)-2-oxo-6-phenyl-2,3,4,7-

tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-

diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-


diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; and

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide.

12. (original) A compound of formula (II):



(II)

wherein:

R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_{2-4} alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional substitutions are made with 0, 1, 2 or 3 R^c;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^c;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^c;

R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃,

C₁₋₆alkyl, or C₁₋₆alkoxy;

R², R³, R⁶ and R⁷ are independently selected from H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C₁₋₃alkylaryl, optionally substituted C₁₋₃alkylheterocycle, optionally substituted C₁₋₆alkyl, or optionally substituted C₃₋₆ cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R², R³, R⁶ and R⁷ are aromatic or heteroaromatic;

R⁴ is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C₁₋₆alkyl, C₃₋₆ cycloalkyl, or CR⁹R¹⁰R¹¹;

R⁵ is C₁₋₃alkylR¹² or CH(OH)R¹³;

R⁹, R¹⁰ and R¹¹ are, at each occurrence independently selected from H, F, C₁₋₄alkyl, OH, OCH₃, SH, SCH₃, CH₂SCH₃;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R¹³ is C₁₋₆alkyl or R¹²;

or a pharmaceutically acceptable salt thereof.

13. (currently amended) A compound of ~~formula (H)~~ claim 12, wherein:

R¹ is selected from H, or optionally substituted alkyl wherein such optional substitution is made with 0, 1, or 2 substituents selected from C₁₋₆cycloalkyl, C₁₋₆cycloalkoxy, or phenyl;

R², R³, R⁶ and R⁷ are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R², R³, R⁶ and R⁷ are aromatic;

R⁴ is H, or C₁₋₆alkyl;

R⁵ is C₁₋₃alkylR¹² or C₁₋₆alkyl;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy;

or a pharmaceutically acceptable salt thereof.

14. (currently amended) A compound of claim 12, wherein:

R^1 is selected from H, $-C_{1-6}$ alkyl, $-(CH_2)_2OCH_3$, $-CH_2$ -phenyl, $-CH_2C_{1-6}$ cycloalkyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH_3 ;

R^4 is H, or C_{1-6} alkyl;

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 ;

or a pharmaceutically acceptable salt thereof.

15. (original) A compound of claim 12, wherein:

R^1 is selected from $-C_{1-3}$ alkyl, or $-CH_2C_{1-4}$ cycloalkyl.

16. (original) A compound of claim 12, wherein:

R^1 is selected from methyl or $-CH_2$ cyclopropane.

17. (original) A compound of claim 12, wherein:

R^e is at each occurrence independently selected from F, Cl, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy.

18. (original) A compound of claim 12, wherein:

R^2 is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.

19. (original) A compound of claim 12, wherein:

R^3 , R^6 and R^7 are H.

20. (original) A compound of claim 12, wherein:

R^4 is C_{1-6} alkyl.

21. (currently amended) A compound of claim 12, wherein:

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 .

22. (currently amended) A compound of ~~formula (II)~~ claim 12 selected from:

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-

tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;


N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; and

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide.

23. (original) A compound of formula (III):



(III)

wherein:

R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_{2-4} alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional substitutions are made with 0, 1, 2 or 3 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^e;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C_{1-6} alkyl, or C_{1-6} alkoxy;

R^2 , R^3 and R^7 are independently selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C_{1-6} alkyl, or optionally substituted C_{3-6} cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R^2 , R^3 and R^7 are aromatic or heteroaromatic;

R^6 is independently selected from H, optionally substituted C_{1-3} alkylaryl, optionally

substituted C₁₋₃alkylheterocycle, optionally substituted C₁₋₆alkyl, or optionally substituted C₃₋₆cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties;

R⁴ is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C₁₋₆alkyl, C₃₋₆cycloalkyl, or CR⁹R¹⁰R¹¹;

R⁵ is -C₁₋₆alkyl, -C₁₋₃alkylR¹² or CH(OH)R¹³;

R⁹, R¹⁰ and R¹¹ are, at each occurrence independently selected from H, F, C₁₋₄alkyl, OH, OCH₃, SH, SCH₃, CH₂SCH₃;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R¹³ is C₁₋₆alkyl or R¹²;

or a pharmaceutically acceptable salt thereof.

24. (currently amended) A compound of ~~formula (II)~~ claim 23, wherein:

R¹ is selected from H, or optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from C₁₋₆cycloalkyl, C₁₋₆cycloalkoxy, or phenyl;

R², R³, R⁶ and R⁷ are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R², R³, R⁶ and R⁷ are aromatic;

R⁴ is H, or C₁₋₆alkyl;

R⁵ is -C₁₋₆alkyl or -C₁₋₃alkylR¹²;

R¹² is phenyl substituted with 0, 1, 2 or 3 R^e;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy;

or a pharmaceutically acceptable salt thereof.

25. (currently amended) A compound of ~~formula (III)~~ claim 23, wherein:

R¹ is selected from H, -C₁₋₆alkyl, -(CH₂)₂OCH₃, -CH₂-phenyl, or -CH₂C₁₋₆cycloalkyl;

R², R³, R⁶ and R⁷ are independently selected from H, or a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH₃;

R⁴ is H, or C₁₋₆alkyl;

R⁵ is ~~C₁₋₆alkyl~~, C₁₋₆alkyl or -C₁₋₃alkylR¹² wherein R¹² is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH₃; or a pharmaceutically acceptable salt thereof.

26. (currently amended) A compound of claim 23, wherein:

R¹ is ~~C₁₋₆alkyl~~, C₁₋₆alkyl or -CH₂C₁₋₄cycloalkyl.

27. (original) A compound of claim 23, wherein:

R¹ is methyl or -CH₂cyclopropane.

28. (original) A compound of claim 23, wherein:

R^e is, at each occurrence independently selected from F, Cl, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy.

29. (original) A compound of claim 23, wherein:

R² is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.

30. (original) A compound of claim 23, wherein:

R³, R⁶ and R⁷ are H.

31. (original) A compound of claim 23, wherein:

R⁴ is C₁₋₆alkyl.

32. (currently amended) A compound of claim 23, wherein:

R⁵ is ~~C₁₋₆alkyl~~, C₁₋₆alkyl or -C₁₋₃alkylR¹² wherein R¹² is a substituted phenyl, wherein such ~~substituent~~ substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH₃.

33. (currently amended) A compound of ~~formula (III)~~ claim 23 selected from:

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*R*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*R*,7*S*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*R*,7*R*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide (3□);

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*R*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*R*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*R*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*R*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*R*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-

phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-

alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-

yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide; and

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide.

34-38. (cancelled).

39. (currently amended) A method of treatment of a human or animal suffering from ~~neurological disorders~~ a neurological disorder associated with β -amyloid production comprising administering to ~~a host in need of such treatment~~ the human or animal a therapeutically effective amount of a compound ~~as defined in any one of claims 1 to 33~~ of claim 1.

40. (currently amended) A method of treating Alzheimer's disease in a patient comprising administering to a patient ~~in need of such treatment~~ an effective amount of a compound ~~as defined in any one of claims 1 to 33~~ of claim 1.

41. (currently amended) A method of treating dementia in a patient comprising administering to a patient ~~in need of such treatment and~~ an effective amount of a compound ~~as defined in any one of claims 1 to 33~~ of claim 1.

42. (currently amended) A method of treating age associated cognitive decline, mild cognitive impairment, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's Syndrome in a patient comprising administering to a patient ~~in need of such treatment and~~ an effective amount of a compound ~~as defined in any one of claims 1 to 33~~ of claim 1.

43. (currently amended) A method of preventing Alzheimer's disease a patient comprising administering to a patient at risk of developing Alzheimer's disease an effective amount of a

compound as ~~defined in any one of claims 1 to 33~~ of claim 1.


44. (currently amended) A method of preventing dementia in a patient comprising administering to a patient at risk of developing dementia an effective amount of a compound as ~~defined in any one of claims 1 to 33~~ of claim 1.

45. (currently amended) A method of preventing age associated cognitive decline, mild cognitive impairment, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's Syndrome in a patient comprising administering to a patient at risk of developing a learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's Syndrome an effective amount of a compound as ~~defined in any one of claims 1 to 33~~ of claim 1.

46. (currently amended) A method for inhibiting γ -secretase activity comprising administering to a host ~~in need of such inhibition~~ a therapeutically effective amount of a compound as ~~defined in any one of claims 1 to 33~~ of claim 1.

47. (currently amended) A pharmaceutical composition ~~comprising~~ comprising a compound as ~~defined in any one of claims 1 to 33~~ of claim 1 or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, together with at least one ~~pharmaceutically~~ pharmaceutically acceptable carrier, diluent or ~~excipient~~ excipient.


48. (currently amended) A process for preparing a compound of formula 1f



1f


comprising reacting a ~~compound of formula 1d~~ tert-butyl[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]carbamate with TFA trifluoroacetic acid.

49. (currently amended) A process for preparing a compound of formula 1



1


comprising reacting a compound of formula 1f



1f

and *N*-[(3,5-difluorophenyl)acetyl]-L-alanine with HOBt-hydrate, ~~EDAC.HCL~~ EDAC.HCl and *N*-methyl morpholine.


50. (currently amended) A process for preparing a compound of formula 2e



2e

comprising reacting ~~a compound of formula 2e~~ benzyl [(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]carbamate with H₂, H₂ and Pearlman's Catalyst in ETOH.

51. (currently amended) A process for preparing a compound of formula 2




2

comprising reacting ~~a compound of formula 2e~~ (3*S*,7*S*)-3-amino-1-methyl-7-phenylazepan-2-one and *N*-[(3,5-difluorophenyl)acetyl]-L-alanine with HOBt-hydrate, ~~EDAC.HCL~~ EDAC.HCl and

N-methyl morpholine.


52. (currently amended) A process for preparing a compound of formula 11f (3R,7S)-3-amino-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-1,3,4,7-tetrahydro-2H-azepin-2-one comprising reacting a compound of formula 11d



11d

with ~~H₂NNH₂~~ H₂NNH₂ in MeOH.

53. (currently amended) A process for preparing a compound of formula 11A



11A

comprising reacting a compound of formula 11f (3R,7S)-3-amino-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-1,3,4,7-tetrahydro-2H-azepin-2-one and *N*-[(3,5-difluorophenyl)acetyl]-L-alanine with with HOBt-hydrate, ~~EDAC.HCL~~ EDAC.HCl and N-methyl morpholine.